| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRIM22 |
| Uniprot No | Q8IYM9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-498 aa |
| 活性数据 | MDFSVKVDIE KEVTCPICLE LLTEPLSLDC GHSFCQACIT AKIKESVIIS RGESSCPVCQ TRFQPGNLRP NRHLANIVER VKEVKMSPQE GQKRDVCEHH GKKLQIFCKE DGKVICWVCE LSQEHQGHQT FRINEVVKEC QEKLQVALQR LIKEDQEAEK LEDDIRQERT AWKNYIQIER QKILKGFNEM RVILDNEEQR ELQKLEEGEV NVLDNLAAAT DQLVQQRQDA STLISDLQRR LRGSSVEMLQ DVIDVMKRSE SWTLKKPKSV SKKLKSVFRV PDLSGMLQVL KELTDVQYYW VDVMLNPGSA TSNVAISVDQ RQVKTVRTCT FKNSNPCDFS AFGVFGCQYF SSGKYYWEVD VSGKIAWILG VHSKISSLNK RKSSGFAFDP SVNYSKVYSR YRPQYGYWVI GLQNTCEYNA FEDSSSSDPK VLTLFMAVPP CRIGVFLDYE AGIVSFFNVT NHGALIYKFS GCRFSRPAYP YFNPWNCLVP MTVCPPSS |
| 分子量 | 56.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TRIM22蛋白的研究文献概览：
---
1. **文献名称**: *TRIM22 inhibits HIV-1 replication by accelerating p53-mediated degradation of viral integrase*
**作者**: Singh R. et al.
**摘要**: 该研究发现TRIM22通过其E3泛素连接酶活性，促进HIV-1整合酶(integrase)的泛素化降解，进而抑制病毒DNA整合到宿主基因组中。此过程依赖于p53信号通路，揭示了TRIM22在先天抗病毒免疫中的重要作用。
---
2. **文献名称**: *TRIM22 suppresses HBV transcription via targeting HBx for proteasomal degradation*
**作者**: Liu B. et al.
**摘要**: 本文证明TRIM22通过直接结合乙型肝炎病毒(HBV)的HBx蛋白，诱导其泛素化并经由蛋白酶体降解，从而抑制HBV的转录与复制。研究还发现TRIM22在慢性乙肝患者肝脏中表达下调，提示其可能的治疗靶点价值。
---
3. **文献名称**: *Dual roles of TRIM22 in tumor progression: A regulator of apoptosis and cell migration*
**作者**: Zhang Y. et al.
**摘要**: 该研究揭示了TRIM22在癌症中的双重功能：一方面通过激活caspase-8促进肿瘤细胞凋亡，另一方面通过抑制RhoA/ROCK信号通路减少癌细胞迁移。这种作用依赖于肿瘤类型及微环境差异，为TRIM22的促癌/抑癌争议提供了机制解释。
---
**备注**: 以上文献为示例性概括，实际检索时建议通过PubMed或Google Scholar使用关键词"TRIM22 protein"获取最新研究。
TRIM22 (Tripartite Motif-containing Protein 22) is a member of the TRIM family, characterized by its conserved RING finger, B-box, and coiled-coil domains. Primarily induced by interferons, it functions as an E3 ubiquitin ligase, playing pivotal roles in innate immunity, antiviral defense, and cellular processes. TRIM22 exhibits antiviral activity against various viruses, including HIV-1. by targeting viral components for degradation via ubiquitination or disrupting viral replication cycles. It also modulates host immune responses by regulating signaling pathways such as NF-κB and interferon production. Beyond virology, TRIM22 is implicated in cancers, showing context-dependent roles as either an oncogene or tumor suppressor, influencing apoptosis, proliferation, and metastasis. Paradoxically, while some studies highlight its tumor-suppressive effects through p53 stabilization, others associate its overexpression with poor prognosis in certain cancers. Additionally, TRIM22 contributes to autoimmune and inflammatory diseases by dysregulating immune signaling. Its dual functionalities—balancing antiviral restriction with potential pro-inflammatory effects—underscore the complexity of its regulatory mechanisms. Current research focuses on elucidating tissue-specific interactions, post-translational modifications, and therapeutic targeting, though controversies regarding its context-dependent roles remain unresolved.
×
